Takeda, arcotatug tavatecan, TAK-921, IBI343, gastric cancer, gastroesophageal junction adenocarcinoma, CLDN18.2, antibody-drug conjugate, ADC, G-HOPE-001, Phase 3 clinical trial, oncology

Osaka, Japan, and Cambridge, Massachusetts, U.S., October 23, 2026 Takeda announced positive Phase 3 results for arcotatug tavatecan (TAK-921;...